DKSH Korea debuts at the Korean Society of Nephrology(KSN) International Congress after having taking over an international congress since acquiring Kyowa Kirin Korea’s renal portfolio. At the congress, DKSH presented Orkedia (Evocalcet) as a new treatment option for kidney diseases with fewer side effects and improved medication adherence compared to existing therapies. This participation underlines the aim of DKSH Korea Business Unit Healthcare to become the trusted partner in the field of kidney disease treatment.
Seoul, Korea, June XX, 2025 – DKSH Korea, a leading Market Expansion Services provider, participated in the 2025 KSN International Congress. The event was held from June 19 to 22 at COEX in Seoul, Korea. This marks DKSH Korea’s first official involvement in this international medical congress since taking responsibility for Kyowa Kirin Korea’s renal product portfolio in last year.
At the congress, DKSH Korea introduced the company and its product offerings, while strengthening engagement with nephrology specialists across the country. During the Industry Symposium on June 20, Professor Jong-Soo Lee of the University of Ulsan and Professor Ji-Yong Jung of Gachon University Gil Medical Center delivered a presentation on the clinical value of Orkedia (ingredient: Evocalcet), a treatment for secondary hyperparathyroidism which DKSH distributes in the market.
Professor Jung emphasized, “Orkedia is a new-generation calcimimetic developed to overcome the limitations of existing therapies such as cinacalcet. It offers higher absorption and significantly fewer gastrointestinal side effects, which can lead to better medication adherence in real-world clinical settings.”
He added, “Multiple clinical studies have demonstrated Orkedia’s efficacy in lowering parathyroid hormone levels and its strong safety profile. It is increasingly being recognized as a promising option to improve long-term treatment continuity.”
A representative from DKSH Korea stated, “Our participation in this year’s congress marks a significant milestone as we officially expand our footprint in the domestic renal therapeutics market. We are proud to be the partner for this product in Korea, and we appreciate that researchers underlined its high quality. We are committed to becoming a trusted partner to both healthcare professionals and patients.”
The Korean Society of Nephrology International Congress is the largest academic event in the Korean nephrology field, attracting more than 1,000 nephrologists and industry professionals annually. It serves as a key platform for sharing the latest clinical insights and treatment advancements.
About DKSH
DKSH was established in 1865 and is headquartered in Switzerland. As a leading provider of Market Expansion Services, DKSH operates in 37 countries with 870 business locations worldwide. The company offers a wide range of services to businesses seeking stable outsourcing solutions for growth in various industries. DKSH's operations are divided into four key business units: Consumer Goods, Healthcare, Performance Materials, and Technology. The company is committed to sustainable and profitable growth, with a clear strategy to meet the specific needs and diversity of its partner industries. https://www.dksh.com/kr-ko/home